In parenchymatous liver disease, antithrombin III was the most frequently abnormal parameter (78.6% of the patients) and liver cirrhosis was more frequently associated with an abnormality of antithrombin III value than was acute hepatitis (91.1% vs 38 4% respectively).
The probability of presenting a hepatocellular jaundice according to the blood coagulation test results at admission time is shown in Table 3 . Normotest and Thrombotest were poor discriminant coagulation parameters. When a low fibrinogen level was observed (39.8% of the patients with jaundice), the probability of presenting a hepatocellular jaundice was 97%. As far as a low antithrombin III value was concerned (52.7% of the patients with jaundice), the probability of presenting a hepatocellular jaundice was 92% and this probability decreased to 27% when antithrombin III value was normal. As is shown in Figure 3 of both antithrombin III, plasminogen, and alpha2 antiplasmin at admission time. Table 4 shows the prognostic significance of the blood coagulation tests in hepatocellular jaundice. A normal value of antithrombin III, plasminogen or alpha2 antiplasmin at admission time was never associated with death while normal values for Normotest, Thrombotest or fibrinogen were associated with a 12.5%, 12.5%, and 18X2% death r-ate respectively. On the other hand, when the blood coagulation test results were abnormal at admission time, the mortality rate ranged from 35-40%. In cholestatic jaundice (group II), the blood coagulation tests which were studied had no prognostic significance and abnormalities of Normotest and of Thrombotest depended upon the duration of the obstructive disease (abnormal in 90% of the cases of jaundice persisting for more group.bmj.com on July 8, 2017 -Published by http://gut.bmj.com/ Downloaded from cholestatic jaundice. An abnormal value of antithrombin III strongly suggested the presence of parenchymatous liver disease while a normal value was in favour of jaundice due to another cause. Further investigations will be required to determine the discriminant value of antithrombin III compared with the classical enzymatic patterns in differentiating the origin of jaundice.
In our study, a relation between antithrombin III value and fibrinogen concentration was observed. Most of the patients with a low fibrinogen concentration had a low antithrombin III value and the majority of the patients with a normal antithrombin III value had a normal fibrinogen concentration. Nevertheless, one third of the patients with a normal fibrinogen value exhibition an abnormal value of antithrombin III and most of these patients presented an abnormality of Thrombotest. Aurousseau has previously shown a close correlation between plasma antithrombin III and prothrombin concentrations in patients with liver cirrhosis." These observations suggested that antithrombin III values were abnormal in both severe hepatic failure (with low fibrinogen concentrations) and in moderate liver insufficiency (with normal fibrinogen concentrations and abnormal values of Thrombotest).
The main interest of the blood coagulation tests which were studied, was in their prognostic significance in parenchymatous liver disease. Normal values of antithrombin III, plasminogen or alpha2 antiplasmin were never associated with death and therefore indicated a good prognosis. On the other hand, abnormal values of antithrombin III, plasminogen or alpha2 antiplasmin at admission time, were associated with a death rate of 36*4%, 39%, and 40% respectively. -Normotest, Thrombotest, and fibrinogen determinations did not allow a prediction of the patients' prognosis with the same accuracy.
In conclusion, among the blood coagulation tests which were studied, the antithrombin III was the most discriminant factor in differentiating hepatocellular from cholestatic jaundice.
Furthermore, antithrombin III, plasminogen, and alpha2 antiplasmin appeared to provide a good index of the liver cell function and were superior to the Normotest, Thrombotest, and fibrinogen concentration in predicting the prognosis of the patients at admission time.
